Pages

Look Towards A New Future

Oct 4, 2012

Global GPS IC Market 2011-2015

TechNavio's analysts forecast the Global GPS IC market to grow at a CAGR of 7.5 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing use of GPS ICs in smartphones. The Global GPS IC market has also been witnessing the development of multifunctional GPS ICs. However, the lack of accuracy in GPS information could pose a challenge to the growth of this market.

TechNavio's report, the Global GPS IC Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global GPS IC market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Broadcom Corp., CSR Plc., Qualcomm Inc., and Texas Instruments Inc.

Other vendors mentioned in the report: Analog Devices Inc., Maxim Integrated Products Inc., and RF Micro Devices.

Key questions answered in this report:
  • What will the market size be in 2015 and at what rate will it grow?
  • What key trends is this market subject to?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the opportunities and threats faced by each of these key vendors?
  • What are the strengths and weaknesses of each of these key vendors? 
Get a copy of this report @ http://www.reportsnreports.com/reports/195669-global-gps-ic-market-2011-2015.html

Non-Life Insurance in Malaysia, Key Trends and Opportunities to 2016

The report provides in depth market analysis, information and insights into the Malaysian non-life insurance market, including:
  • The Malaysian non-life insurance market’s growth prospects by non-life insurance categories
  • The various distribution channels in the Malaysian non-life insurance market
  • The competitive landscape in the non-life insurance market in Malaysia
  • A description of the non-life reinsurance market in Malaysia
Executive summary

The expansion of the Malaysian non-life insurance segment was strongly influenced by the country’s GDP growth and the increasing penetration rate of the Malaysian insurance industry. Moreover, the growth of the industry is also expected to be driven by increased risk awareness and propensity for risk avoidance among the Malaysian population. The growth of the country’s property and automobile industries, rising employment levels and anticipated industrial growth over the forecast period are also expected to drive the growth of the non-life insurance segment. In 2011, the motor insurance category accounted for the largest proportion of the Malaysian non-life segment.

Get a copy of this report @ http://www.reportsnreports.com/reports/155944-non-life-insurance-in-malaysia-key-trends-and-opportunities-to-2016.html

Report Details:

Published: October 2012
No. of Pages: 257
Price:Single User License:US$1950 Corporate User License:US$3900



Scope
This report provides a comprehensive analysis of the non-life insurance market in Malaysia:
  • It provides historical values for Malaysia’s non-life insurance market for the report’s 2007–2011 review period and forecast figures for the 2012–2016 forecast period
  • It offers a detailed analysis of the key sub-segments in Malaysia’s non-life insurance market, along with market forecasts until 2016
  • It covers an exhaustive list of parameters, including written premium, incurred loss, loss ratio, commissions and expenses, combined ratio, frauds and crimes, total assets, total investment income and retentions
  • It analyses the various distribution channels for non-life insurance products in Malaysia
  • Using Porter’s industry-standard “Five Forces” analysis, it details the competitive landscape in Malaysia for the non-life insurance business
  • It provides a detailed analysis of the reinsurance market in Malaysia and its growth prospects
  • It profiles the top non-life insurance companies in Malaysia and outlines the key regulations affecting them
Key highlights
  • The expansion of the Malaysian non-life insurance segment was strongly influenced by the country’s GDP growth and the increasing penetration rate of the Malaysian insurance industry.
  • In 2011, the motor insurance category accounted for the largest proportion of the Malaysian non-life segment.
  • The growth of the industry is also expected to be driven by increased risk awareness and the propensity for risk avoidance among the Malaysian population.
  • Although the agencies distribution channel dominates Malaysian non-life insurance, bancassurance is expected to record the strongest growth over the forecast period.
Reasons to buy
  • Make strategic business decisions using historic and forecast market data related to the Malaysian non-life insurance market and each sector within it
  • Understand the demand-side dynamics, key market trends and growth opportunities within the Malaysian non-life insurance market
  • Assess the competitive dynamics in the non-life insurance market, along with the reinsurance segment
  • Identify the growth opportunities and market dynamics within key product categories
  • Gain insights into key regulations governing the Malaysian insurance market and its impact on companies and the market's future

Progress in Target Validation

Target validation is one of the first and most important steps in drug discovery; poor target validation is a major factor in clinical stage attrition. Target validation involves the thorough assessment of a molecular target, evaluating its physiology, pathology, and pharmacology and determining its role in altering the disease phenotype. This report assess technological advances in the field.

Features and benefits
  • Discover how and patient-derived human primary cells and induced pluripotent stems cells lines are being used to validate new drug targets.
  • Understand how RNAi technology can be applied to both in vitro and in vivo settings to confirm the involvement of targets in disease pathways.
  • Identify the omic technologies that are being used reveal new options for modulating disease pathways and new interactions of known drugs.
  • Understand the power of high-content screening in probing functional changes occurring at the cellular level.
  • Assess the role of bioinformatics in managing the vast quantities of data that are being created through target validation projects. 
Get a copy of this report @ http://www.reportsnreports.com/reports/195678-progress-in-target-validation.html

Report Details:

Published: September 2012
No. of Pages: 44
Price:Single User License:US$2875 Corporate User License:US$10781


Highlights

In recent years there has been a paradigm shift, with greater emphasis placed on the validation of a target in human cell and animal disease models prior to screening for lead compounds. This facilitates in-depth knowledge of the underlying biology of a disease and allows evaluation of upstream and downstream pathways of new targets.

RNAi-based technologies offer high throughput, a high-predictive value, relatively low cost, short experimental times, and the ability to knock down several genes in vitro and in vivo.

Improvements in molecular imaging and bioinformatics have enabled high-content screening to become more widely applied to measure phenotypic endpoints, allowing structural and biochemical changes within cells, tissues, organs, or whole organisms to be visualized in real time, leading to improvements in target validity.

Your key questions answered
  • What novel technologies have been developed to improve target validation in vivo?
  • What role do systems biology and network pharmacology have in target valdiation?
  • Which companies are leading the field in the use of in vivo models in target validation?
  • What opportunities do stem cells offer for validating targets?

Product Profiles: Top 20 Oncology Therapy Brands 2011-21

The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. The treatment of cancer has shifted away from mass market blockbuster cytotoxic drugs toward a more personalized therapy approach. However, government austerity packages could see slower commercial growth and larger generic erosion of key brands.

Features and benefits
  • Assess detailed drug information for the leading oncology brands, including detailed clinical trial information for each approved indication
  • Understand the key factors that led to the success of the top 20 oncology therapy brands and the obstacles that they have encountered
  • Gain insight into the clinical and commercial attractiveness for each of the branded drugs and how this will affect their future sales
Get a copy of this report @ http://www.reportsnreports.com/reports/195675-product-profiles-top-20-oncology-therapy-brands-2011-21.html

Report Details:

Published: September 2012
No. of Pages: 157
Price:Single User License:US$11400 Corporate User License:US$28500



Highlights

Targeted therapies comprise 60% of the top 20 brands in 2011 with Roche’s monoclonal antibody franchise maintaining the top three positions. A potential to demonstrate improved clinical efficacy with reduced off-target toxicity, combined with an ability to demand higher prices, makes this drug class clinically and commercially attractive.

An aging cytotoxic market means that cytotoxic brands are becoming less commercially attractive. In the past few years many of the blockbuster cytotoxics have come off-patent and now face generic erosion. As developers turn their attention toward new targeted therapies the number of new cytotoxics entering the market has decreased.

Antihormonal therapies have high clinical attractiveness, but despite strong sales they are limited to two indications. Effective lifecycle management has ensured that sales remain high despite patent expiries in almost every major market.

Your key questions answered
  • Product profiles and development overviews detailing companies involved and the key clinical data leading to each approval
  • Overview of brand positioning in marketed indications relative to competitors and in terms of ability to meet unmet needs
  • SWOT analysis of each brand in the seven major market top 20
  • In depth assessment of each brand’s clinical and commercial attractiveness, including Datamonitor’s drug assessment charts

Fruit Market | Next-Generation Superfruits

This report examines the emerging market of superfruits within the global food and drinks market, analyzing data from four metrics: product launches, patent applications, health claim applications, and clinical trial data. This will enable manufacturers to assess the emerging trends and growth opportunities within the superfruit food and drinks landscape.

Features and benefits
  • Use patent application data to see which superfruits are provoking the most interest in terms of research and what is being deemed patentable.
  • Use product launch data to identify the target areas for existing superfruit-based products. Understand the product breakdown by category.
  • Assess EFSA's opinions and understand what types of claims are being made about which superfruits.
  • Identify three up-and-coming superfruits as “ones to watch” in the future.
Get a copy of this report @ http://www.reportsnreports.com/reports/195677-next-generation-superfruits.html

Report Details:

Published: September 2012
No. of Pages: 90
Price:Single User License:US$2875 Corporate User License:US$10781 



Highlights

Blueberry and pomegranate are the most popular superfruits in new food and drink launches. But novel fruits are gaining ground, with chokeberry, jujube, and seabuckthorn being notable examples. Over 400 new food and drink products containing seabuckthorn were launched in 2009–12, the majority of which hit shelves in Russia, Germany, and France.

A high proportion of health claims involving superfruits have been specifically about antioxidants, with over one in 10 claims submitted to EFSA addressing antioxidant properties. Although many superfruit ingredients have been lauded for their cellular protection properties, only acerola is associated with an endorsed health claim by EFSA.

According to the Cochrane Library, a significant 63% of clinical trials undertaken on superfruits in the period 2009 to 2012 were able to establish a cause and effect relationship. This should prompt further testing in future to establish the positive roles superfruits play in managing certain health conditions.

Your key questions answered
  • What are the more unusual superfruits that have potential to be successfully applied to food and drinks products?
  • What health claims are being made about superfruits and how will these impact food and drinks players?
  • What clinical trials are being undertaken on superfruits and how can these be useful to food and drinks companies?
  • What patent applications have recently been filed on these superfruits and what will be the impact on their FMCG usage?
  • How will regulations impact the sale of these superfruits in global markets?

Oct 1, 2012

Non-Life Insurance in Indonesia, Key Trends and Opportunities to 2016

Synopsis

The report provides in depth market analysis, information and insights into the Indonesian non-life insurance market, including:
  • The Indonesian non-life insurance market’s growth prospects by non-life insurance categories
  • The various distribution channels in the Indonesian non-life insurance market
  • The competitive landscape in the non-life insurance market in Indonesia
  • A description of the non-life reinsurance market in Indonesia
Executive summary

The Indonesian non-life insurance segment grew robustly during the review period. The increase was a result of the favorable regulatory framework for non-life insurance products, such as motor insurance, workers' compensation and passenger accident insurance. This was further supported by the rise in passenger car sales and strong economic development in the country as GDP grew during the review period. These factors are also expected to support the segment over the forecast period.

Buy a copy of this report @ http://www.reportsnreports.com/reports/194828-non-life-insurance-in-indonesia-key-trends-and-opportunities-to-2016.html

Report Details:

Published: September 2012
No. of Pages: 251
Price:Single User License:US$1950 Corporate user License:US$3900



Scope

This report provides a comprehensive analysis of the non-life insurance market in Indonesia:
  • It provides historical values for Indonesia’s non-life insurance market for the report’s 2007–2011 review period and forecast figures for the 2012–2016 forecast period
  • It offers a detailed analysis of the key sub-segments in Indonesia’s non-life insurance market, along with market forecasts until 2016
  • It covers an exhaustive list of parameters, including written premium, incurred loss, loss ratio, commissions and expenses, combined ratio, frauds and crimes, total assets, total investment income and retentions
  • It analyses the various distribution channels for non-life insurance products in Indonesia
  • Using Porter’s industry-standard “Five Forces” analysis, it details the competitive landscape in Indonesia for the non-life insurance business
  • It provides a detailed analysis of the reinsurance market in Indonesia and its growth prospects
  • It profiles the top non-life insurance companies in Indonesia and outlines the key regulations affecting them
Key highlights
  • The growth in the Indonesian non-life insurance segment was a result of the favorable regulatory framework for non-life insurance products, such as motor insurance, workers' compensation and passenger accident insurance.
  • The number of passenger car sales increased from 426,300 in 2007 to 602,000 in 2011 after a decline in 2009 due to the financial downturn. This increase supported the motor insurance category and encouraged more business during the review period.
  • The Indonesian non-life insurance segment currently has one of the world’s lowest penetration rates.
  • Until the economic crisis in 2009, Indonesia registered sustained economic growth with rising consumer incomes during the review period. The country also recorded an increase in the size and purchasing power of its middle class.
Reasons to buy
  • Make strategic business decisions using historic and forecast market data related to the Indonesian non-life insurance market and each sector within it
  • Understand the demand-side dynamics, key market trends and growth opportunities within the Indonesian non-life insurance market
  • Assess the competitive dynamics in the non-life insurance market, along with the reinsurance segment
  • Identify the growth opportunities and market dynamics within key product categories
  • Gain insights into key regulations governing the Indonesian insurance market and its impact on companies and the market's future

Brazil Pharmaceutical Market Overview – Strong market growth continues, but regulatory risks increase

Key growth drivers in Brazil include the expanding population, improved access to healthcare, and the burgeoning middle class which is increasingly opting for branded drugs. Consequently, Big Pharma is targeting Brazil to offset slowing sales growth in more developed markets.

Features and benefits
  • Analysis of population demographics, economic wealth, disease burden, level of industrialization, and political structure in Brazil.
  • Insight into the healthcare system, drug regulation, drug pricing, drug reimbursement, and intellectual property position in Brazil.
  • Assesses the generics and biosimilars landscape in terms of regulatory issues, level of penetration, and key players in Brazil.
  • Overview of key market segment sales and top companies, and R&D and manufacturing infrastructure for the leading pharmaceutical companies in Brazil. 
Buy a copy of this report @ http://www.reportsnreports.com/reports/194883-brazil-pharmaceutical-market-overview-strong-market-growth-continues-but-regulatory-risks-increase.html

Report Details:

Published: September 2012
No. of Pages: 139
Price:Single User License:US$5700 Corporate User License:US$14250




Highlights

Overall, health expenditure as a percentage of GDP is increasing which reflects the fact that healthcare and access to treatment (and thus pharmaceutical spending) is an increasing priority for the government.

Intellectual property protection remains problematic for branded pharma, with issues associated with patent linkage, drawn-out patent reviews, conflict between the two agencies involved in assessing patent applications, and the fact that there is no set period of data exclusivity.

Strong market growth in conjunction with improving regulatory standards has led to Brazil becoming a hotbed of investment from both multinational and domestic companies. Big Pharma players are gaining a stronger presence through M&A, benefiting from strong brand image of the local manufacturers.

Your key questions answered
  • How is the regulatory landscape in Brazil changing and what is is the impact of pricing and reimbursement controls on market access in Brazil?
  • What are the drivers and resistors of generic and biosimilars uptake in the Brazilian pharmaceutical market?
  • Which pharmaceutical market segments in Brazil have the fastest growth rates?

Maintaining Growth in the Renewables Sector

This report looks at the evolution of renewable energy, from the factors that have led to significant and continuing growth, to those that may curb growth in the short term. The report identifies growing awareness and acceptance of renewables as a driver, but concludes that the lack of a stable investment environment could limit this growth and that a broader, longer-term strategy is needed.

Features and benefits
  • Gain insight into where the renewables sector is now and an overview of current trends broken down by fuel, region, country, end-user, and generator.
  • Understand likely future trends and the key issues leading to growth, including investment, cost-equivalence with fossil fuels, and energy security.
  • Understand the main factors that could cause renewables development to falter, including failure to disaggregate renewable energy by fuel.
  • Gain an overview of principal alternatives to renewables development and the strengths and weaknesses of these alternatives.
  • Gain recommendations and the basic components of the strategy needed at a national level to ensure continuing renewables growth. 
Buy a copy of this report @ http://www.reportsnreports.com/reports/194886-maintaining-growth-in-the-renewables-sector.html

Report Details:
Published: September 2012
No. of Pages: 72
Price:Single User License:US$2875 Corporate User license:US$10781


Highlights


The days when renewables development was seen as a question of whether to implement a specific renewable in a specific location are gone: renewables need to be seen as part of a portfolio of energy resources that may include other modern conventional technologies (including natural gas and CCS).

The continued development of renewables requires strategic vision and investment in infrastructure and technology: most obviously, smart grid and energy storage. However, new generation biofuels technology is needed to kickstart this segment of the renewables market.

The move toward the next generation of technologies is unlikely to be possible without strong signals from states and governments that they will be supported.

Your key questions answered
  • Where are renewables now in the overall energy mix and how is this reflected by region and by country?
  • What are the long-term prospects for renewables and which are expected to see the most significant growth over the next decades?
  • What are the principal policy and investment issues?
  • What are the key technological and structural obstacles to renewables implementation?
  • What changes need to be put in place at government level to ensure continuing renewables success?

Sep 30, 2012

Understanding City and Regional Health Markets in Brazil, Russia, India and China

Highly-detailed and granular healthcare reports provide a unique evaluation of where opportunity and risk can be found

Any assessment of the world’s leading emerging economies must consider the recent economic developments, the health plans which are in place and the challenges that are influencing the progress of the health market.

But analysis which is based on whole country statistics can miss the subtle trends which are influencing the markets on the ground.

Identifying opportunities in local health economies requires detailed knowledge of the economic performance and health infrastructure at a city/provincial/regional level. Being able to see that in the context of the neighbouring districts/regions as well as the national picture, brings focus to areas of opportunity and need.
  • How is the population and wealth distributed?
  • Which states and territories produce the highest levels of GDP?
  • What is the primary and secondary health infrastructure in each region?
  • How is healthcare delivered?
  • What is the role played by private/government health provision at state level?
  • Which regions are better provided for and which still need investment?
Drill down into regional health markets and better understand the opportunities and challenges

BRAZIL - Brazil has made great strides in improving the health of its citizens yet, in common with other emerging markets, distribution of health services is uneven, with wide disparities between regions.

Get a copy of this report @ http://www.reportsnreports.com/reports/194885-understanding-city-and-regional-health-markets-in-brazil-russia-india-and-china.html

Report Details:

Published: September 2012
Price:US$1740



Looking at health expenditure
It is critical for medical and pharmaceutical companies to understand the sometimes confusing funding of healthcare in Brazil. Health expenditure comprises public health expenditure, private health insurance and private out-of-pocket health expenditure. A high proportion of public health expenditure goes towards expensive and complex services, including hospital admissions and diagnostic & therapy services. In recent years, however, public expenditure has shifted towards primary care services.

As public health expenditure has moved towards primary care, the level of access to ambulatory and hospital care has diminished, as public financial resources have not increased at the same level. In 2008, the latest year for which data is available, public health expenditure represented 3.8% of GDP, equal to R$108.9 billion (US$59.3 billion). Alongside the Brazilian health system there is a strong private health insurance sector which, in recent years, has been increasing. Brazil is the second largest insurance market in the world, after the USA.

KEY FACTS
  • The Brazilian economy experienced real growth of around 2.9% in 2011, to be valued at US$2,485 billion, with average per capita GDP of US$12,889. Brazil is currently the world’s 7th largest economy, between France (US$2,773 billion) and the UK (US$2,436 billion).
  • At 194.7 million, the population of Brazil is the fifth largest in the world. Average population growth is around 1.1% per annum. Around 21.6% of the population reside in São Paulo state and 8.4% live in the state of Rio de Janeiro. The 2010 census identified 14.1 million people aged 65 or older, equivalent to 7.4% of the population.
  • In 2011, Brazil spent R$368.2 billion (US$219.8 billion) on healthcare, equivalent to 8.8% of GDP. Private spending accounted for 52.7% of the total, more than half of which was out of pocket spending. Public health spending amounted to US$115.8 billion. Per capita health spending was around US$1,140.

RUSSIA - No one would deny that Russia’s health system has declined since the fall of the Soviet state and for many years was under-funded and poorly developed. Since 2005, Russian authorities have embarked on ambitious plans to improve matters – progress to date, but will they come up to European standards?

Funding is at the heart of Russia’s health improvement plans, and at the beginning of 2011 obligatory medical insurance contributions increased from 3.1% to 5.1%, deductable from salaries. With measures to increase income, has come the challenge of distribution and the recognition that, in common with countries such as India and China, there is a yawning gap between well-provided for cities, and the more remote regions. In 2010, the government introduced the idea of a regional healthcare services modernisation scheme that aims to improve quality and availability of medical service. Healthcare modernisation is well overdue: to put this into context, over 30% of hospitals lack a hot water supply, 8% do not have a drinking water pipeline and 9% lack drainage.

KEY FACTS
  • The Russian Federation is the largest country in the world, with a land area of over 17 million square kilometres, encompassing eleven time zones. After the breakup of the USSR, the Russian Federation retained over 75% of the USSR's total land area and 51% of its population.
  • The population of Russia was estimated at 142.9 million in 2010, an increase of 0.71% over 2009. Prior to 2010, the growth rate remained negative, decreasing by an average of 0.4% each year since 1999.
  • The country is organised into 8 districts which are further subdivided into 82 regions, autonomous areas and republics.

INDIA - India’s 1.21 billion population is distributed across 35 states and union territories, and is growing at 1.6% per year. In terms of landmass, India is approximately one third the size of the USA.

India has an established mainly urban middle class but the bulk of the population have little by way of income and resources. This is exacerbated in India where, despite there being over 45 cities with more than 1 million inhabitants, the majority of the population live rurally in over 638,000 villages – many of them remote and difficult to access. The impact on key health indicators, such as infant mortality, can be clearly seen and despite per capita health spending more than doubling in the last 10 years there is some way to go.

Government health spending has not kept pace with private expenditure with health insurance covering no more than 5%. Out of pocket funding of healthcare remains dominant and the growing number of middle classes have been influential in the growth and success of the many private hospital groups.

CHINA - China: 22 Provinces, four Municipalities and five Autonomous Regions each with an average population of nearly 42 million, each with differing health provision and needs.

China has been a focus of interest for international business for such a long time now that it has become easy to assess markets and economic performance in national terms. Even the much discussed and fast developing urban areas such as Beijing, Shanghai and Tianjin are representative of only a fraction of the widely diverse regional markets to be found elsewhere in the country.

Urban vs. Rural population

Understanding the urban/rural divide in China is critical. The number of cities with over one million inhabitants is significant in every province, with migration from rural areas driven by the boom in manufacturing. The economic strength of cities over rural areas has led to an imbalance of health provision; an imbalance the Chinese government is keen to correct through mechanisms such as the New Co-operative Medical System.

A case in point – Anhui Province: The rural challenge


Anhui Province has 61.3 million people - 4.6% of the national population. The capital and largest city is Hefei, with a population of around 3.4 million and other major cities include Huainan (1.9 million), Huangshan (1.5 million) and Ma'anshan (1.4 million). Anhui has below average rates of hospital beds, physicians and nurses, which can be attributed to the province’s low GDP per capita rate and large rural population.

Private healthcare market in Central Europe 2012


In Bulgaria, Slovakia, the Czech Republic, Poland and Romania, recent conditions have been favorable for the expansion of the market for private healthcare services. These events have led to increased demand by consumers for hospital care, dental and dialysis and a wide range of medical procedures, facilities and delivery systems owned and operated by private business entities. Private companies that sell health insurance and subscription programs used to pay for this medical care are on the upswing as well. The ‘Patients without borders’ directive promises to change the way Central Europeans approach healthcare, as they discover a greater choice of options and providers respond to increased competition for their services.

Private healthcare market in Central Europe 2012, Development forecasts for 2012-2014 offers a unique and comprehensive perspective on the current status and future potential of the pillars of the private healthcare industry in selected Central European countries. Composed of a series of chapters covering diverse topics from market size and value to specific segments such as insurance plans, this report delivers essential data, expert analysis and reliable forecasts to 2014.

The document tracks market growth via data on its size including value from 2008 to the present, and looks ahead with projections on the figures expected until 2014. It lists and analyses the events and trends in economics, demographics and consumer preferences and details the ways in which they are changing the marketplace, and provides updates on changes to legal statutes and regulatory requirements in force within the covered countries.

The publication pays ample attention to the expanding health insurance and medical subscriptions segments, and provides detailed corporate descriptions of the leading providers of these products and services. It examines the supply of private hospitals and health care facilities in each country and projects new investments for the forecast period. 

Prepared as a guide for professionals at work in the private healthcare sectors of Bulgaria, Slovakia, the Czech Republic, Hungary, Poland and Romania, this comprehensive report answers common questions with regard to investment possibilities in the private insurance and medical subscriptions markets, the specific drawbacks to market entry, market conditions for all segments in each country and the predicted development of each market segment during the period to 2014.

The report is an asset in the performance of a variety of business tasks, including assessing the market and preparing for entry, evaluation of investment opportunities, competition research, creating shareholder reports and estimation of revenue. It is also helpful to readers engaged in activities at government, educational and financial institutions.

Get a copy of this report @ http://www.reportsnreports.com/reports/195536-private-healthcare-market-in-central-europe-2012.html

Report Details:

Published: August 2012
No. of Pages: 279
Price:Single User License:US$3500 Corporate User License:US$8750